Delta Opioid Receptor Modulators with Biased Agonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new delta opioid receptor modulators as analgesics with reduced side effects, as well as delta and mu opioid receptor agonists and antagonists for various therapeutic applications, including pain management, immune function, and treatment of neurological and psychiatric conditions, urological issues, and respiratory diseases.
Innovation Solution
Development of compounds of Formula I, which include specific phenyl, naphthyl, pyridinyl, pyrimidinyl, furanyl, and thienyl derivatives, along with their enantiomers, diastereomers, solvates, and pharmaceutically acceptable salts, for use in pharmaceutical compositions and methods for treating opioid receptor-modulated disorders such as pain, inflammation, and immune-related conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional opioids (morphine and related compounds) are used for pain relief, then analgesic effect is achieved, but side effects (nausea, vomiting, respiratory depression, drowsiness, constipation) increase
Solution Approach 1:
The patent segments the opioid receptor system into distinct receptor types (mu, delta, kappa) and develops compounds that selectively target specific receptors. By creating delta-opioid receptor selective agonists and biased agonists that preferentially activate Gi/o pathways while minimizing downstream effects through specific receptor-subtype and pathway-selectivity, the patent reduces side effects while maintaining analgesic efficacy.
Solution Approach 2:
The patent applies local quality by designing compounds with specific molecular structures (Formula I compounds featuring aromatic rings, heterocyclic groups, and specific substituent patterns) that bind preferentially to delta-opioid receptors in pain pathways while having reduced affinity for receptors in areas causing side effects. The biased agonism creates localized activation of beneficial Gi/o pathways while minimizing activation of pathways leading to adverse effects.
2Reliability
If opioid peptides and alkaloid opiates are used to bind opioid receptors, then morphine-like actions are achieved, but differential pharmacological and physiological effects lead to multiple distinct opioid receptor types with varying side effect profiles
Solution Approach 1:
The patent creates compounds of Formula I that serve multiple functions: they act as agonists at delta-opioid receptors for analgesia, can function as antagonists to block opioid effects, and exhibit biased agonism to selectively activate beneficial pathways. These multi-functional compounds address various therapeutic needs (pain management, immune modulation, neurological conditions) through a single molecular platform with可调able activity profiles.
Solution Approach 2:
The patent systematically varies molecular parameters in Formula I compounds (substituents R1-R6, aromatic ring types, heterocyclic groups, linker lengths) to tune receptor selectivity and activity profiles. By changing these structural parameters, the patent optimizes compounds for specific therapeutic applications while minimizing side effects associated with other receptor subtypes.
Data Source
AI summary
Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows:wherein R1, R2, R3, Ra, and Y are defined herein.